Bayer Races Against Time: EMA Takes Up Asundexian as Camelina Expansion Quickens and Supreme Court Decision Nears
11.06.2026 - 18:33:00 | boerse-global.de
Bayer is navigating a pivotal moment on multiple fronts. The European Medicines Agency has formally accepted the marketing application for Asundexian, the blood thinner the company hopes will replace Xarelto as patents on its blockbuster anticoagulant expire. At the same time, the group is accelerating its push into biofuels, scaling up camelina cultivation in North America faster than originally planned. Neither development has been enough to lift the stock out of its slump — shares are down 7.6% year-to-date, trading at 35.12 euros, roughly 8% below the 50-day moving average.
Asundexian Clears a Regulatory Hurdle
The EMA’s validation of the Asundexian filing marks a critical step for Bayer's pharma division. The drug is designed to protect patients who have suffered a stroke, and it is seen as the most promising candidate to fill the revenue gap left by Xarelto’s looming patent cliff. Analysts view the start of the formal review process as a strong signal for future earnings power. On Thursday, the news pushed the stock up 2.28% to 35.92 euros, though the gains have since faded.
Management Overhaul Underway
Alongside the regulatory progress, chief executive Bill Anderson is reshaping the leadership team to shorten decision-making chains. Jana Marlen Ackermann will take over investor relations on August 1, 2026, while her predecessor, Dr. Jost Reinhard, moves to head the radiology business at the same time. The reshuffle is part of a broader efficiency drive that has already touched several layers of the organisation.
Supreme Court Decision Looms Over the Legal Picture
Across the Atlantic, Bayer faces a defining moment in the US legal system. The Supreme Court is expected to rule in June on Monsanto v. Durnell, a case that will determine the fate of roughly 65,000 remaining glyphosate lawsuits. The opt-out deadline for the $7.25 billion settlement passed on June 4, and Bayer aims to secure final court approval of that agreement in July. A favourable ruling would dramatically reduce the legal overhang that has weighed on the stock for years, but the cash outflows required for ongoing litigation are still expected to pressure free cash flow this year.
Should investors sell immediately? Or is it worth buying Bayer?
Technicals in Focus
From a chart perspective, the stock is hovering near a critical juncture. After Thursday’s close it sat just below the 200-day moving average of 35.94 euros. That line has acted as resistance, and the inability to break through reflects broader investor caution. Since the start of the year the shares have lost 5.54% on the Thursday close, and the subsequent drop to 35.12 has extended that decline to 7.6%.
Camelina Gets a Faster Track
Meanwhile, the agricultural side of the business is pushing ahead with a biofuel strategy that has gained urgency from geopolitical developments. The war in Iran has driven up fossil fuel prices and revived interest in renewable alternatives. Bayer manager Peter Muller told Reuters that the company now expects to reach its target of several million acres of camelina in North America earlier than the mid-2030s, provided market demand holds. The oilseed is grown as a cover crop between main growing seasons or on underused land, making it a second-generation feedstock that avoids competition with food production and deforestation risks.
Processing Deal in Sight
Bayer is close to finalising an agreement with an unnamed company that would process the North American camelina harvest, giving farmers the offtake security needed to scale plantings. That deal would build on a partnership announced in May 2026 with bp, under which the two groups will jointly market camelina under the brand newgold®. bp brings refinery know-how, while Bayer contributes seed technology and its farm network. The target market spans biodiesel, renewable diesel and sustainable aviation fuel, which Bayer estimates could grow to 40 billion gallons globally by 2040.
Bayer at a turning point? This analysis reveals what investors need to know now.
Crop Science Delivers Solid Numbers
The operational foundation for the push appears solid. In the first quarter of 2026, the Crop Science division posted currency- and portfolio-adjusted revenue growth of 6.8% to 7.558 billion euros, while divisional EBITDA jumped 17.9% to 3.014 billion euros. For the full year, Bayer expects group sales of 44.5 to 46.5 billion euros and adjusted earnings per share of 4.10 to 4.60 euros.
Market Skepticism Persists
Despite those figures, the stock remains under pressure. It stands roughly 30% below its 52-week high of 49.93 euros reached in February. The camelina story adds a new dimension to the agriculture narrative, but whether it can shift sentiment depends on Bayer converting its acceleration intentions into signed, bankable deals in the coming weeks. Until then, the shares are caught between a promising pipeline, a pending Supreme Court decision, and the market’s demand for visible execution.
Ad
Bayer Stock: New Analysis - 11 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
